Search / Trial NCT06223945

Thrombohemorrhagic Complications of COVID-19

Launched by VOLGOGRAD STATE MEDICAL UNIVERSITY · Jan 24, 2024

Trial Information

Current as of October 04, 2024

Unknown status

Keywords

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Patients with thrombohemorrhagic complications who were treated in a covid hospital
  • Exclusion Criteria:
  • * Cancer patients
  • * Patients who had thrombohemorrhagic disorders before admission to the hospital
  • * Pregnant women
  • * Patients receiving routine anticoagulant and antiplatelet therapy before admission to the hospital

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Volgograd, , Russian Federation

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0